Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SARS-CoV-2 mRNA vaccine (Omicron XBB.1.5)
- Development stage
- Unknown
- Lead developer
- Walvax Biotechnology
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
SARS-CoV-2 mRNA vaccine (Omicron XBB.1.5) is an mRNA-based vaccine developed by Walvax Biotechnology for the prevention of COVID-19. It specifically targets the Omicron XBB.1.5 variant by encoding the genetic sequence for its spike protein. Once administered, the mRNA instructs host cells to produce the spike protein, which serves as an antigen to stimulate the immune system. This process induces the production of neutralizing antibodies and activates cellular immune responses (T-cells) to provide protection against infection and severe disease caused by the XBB.1.5 variant and related lineages. The vaccine has been granted Emergency Use Authorization (EUA) in China to address evolving variants of the virus.
- Other names
- Omicron XBB.1.5 mRNA vaccineWalvax SARS-CoV-2 XBB.1.5 mRNA
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on SARS-CoV-2 mRNA vaccine (Omicron XBB.1.5).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SARS-CoV-2 mRNA vaccine (Omicron XBB.1.5).